ABO2102 is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The sponsor with the most trials is Ruijin Hospital (1). The most-studied condition is Pancreatic Neoplasms.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
NCT06577532 · ClinicalTrials.gov ↗ · Pancreatic Neoplasms, Other Solid Tumors
|
Phase EARLY_PHASE1 | Recruiting | Ruijin Hospital | China |
|
Study of ABO2102 in KRAS-Mutated Solid Tumors
NCT07455617 · ClinicalTrials.gov ↗ · Advanced / Metastatic Solid Tumor
|
Phase 1 | Recruiting | Suzhou Abogen Biosciences Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Ruijin Hospital | 1 |
| Suzhou Abogen Biosciences Co., Ltd | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name ABO2102 as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Ruijin Hospital (1) and Suzhou Abogen Biosciences Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ABO2102 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ABO2102 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ABO2102 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.